Defective HIV copies reshape immune cells through BACH2
A peer-reviewed laboratory study links active but defective HIV DNA to changes that help infected immune-cell clones persist. Viral sequences inserted into BACH2 disrupted regulation of the gene and shifted cell behaviour. The experiments identify an integration-site-dependent mechanism; its contribution to immune disturbances in people receiving treatment remains unresolved.
Science··Morning
Viral DNA can remain active after replication stops
A peer-reviewed laboratory study found that active defective HIV proviruses can reprogram CD4 T cells through effects at their integration sites.[1], [2]
HIV can leave defective copies of its DNA inside the genomes of immune cells. Some of these integrated copies, called proviruses, cannot make new infectious virus but can still produce RNA. A peer-reviewed laboratory investigation examined how this activity changes cell behaviour. Cell models and primary CD4 T cells, an immune-cell population targeted by HIV, were used to study viral sequences inserted into BACH2, a gene that regulates other genes.[1]
BACH2 regulation changes with the insertion
Viral regulatory sequences drove abnormal production of BACH2 protein and bypassed feedback that normally restrains the gene’s activity. Changes across the cells’ gene activity were associated with a proliferative state resembling precursor memory cells. That provides a possible mechanism for the selective persistence of particular infected cell clones. Antiretroviral treatment suppresses viral replication while leaving some transcription from integrated DNA possible. The experiment concerns this continuing interaction between viral sequences and their host cell.[1]
The insertion site changes the cellular outcome
Reducing viral transcription attenuated some effects in the model. Insertion at STAT5B, another regulatory gene, was associated with a different, more effector-like cell state, emphasizing that the BACH2 result cannot describe every defective provirus. The investigation did not test a treatment in patients or measure how much this mechanism contributes to immune disturbances during suppressed HIV infection. Its findings leave the clinical scale of the effect unresolved; reduced transcription in cultured cells does not establish reservoir elimination.[1]
